Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04784715 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT04784715 · ClinicalTrials.gov record · last posted 2026-07-30

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

StatusActive, Not Recruiting
PhasePhase 3
Started2021-04-26
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The study will evaluate the efficacy and safety of trastuzumab deruxtecan (also known as T-DXd, DS-8201a), either alone or in combination with pertuzumab, in treating patients with Human epidermal growth factor receptor 2 (HER2)-positive breast cancer as a first line of treatment in the metastatic setting.

Protocol amendment history 1 change detected by DataLookout

2026-07-31
Primary completion pushed: 2026-07-06 → 2026-11-11
Trial Details
NCT Number NCT04784715
Lead Sponsor AstraZeneca
Collaborators: Daiichi Sankyo
Conditions Breast Cancer; HER2-positive; Metastatic
Enrollment 1,157 participants
Start Date 2021-04-26
Primary Completion 2026-11-11 (estimated)
Study Completion 2029-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-30